Falling plasma S1P tracked with worse survival in emergency department sepsis
Sepsis rarely follows a straight line. Host response, endothelial injury, immune activation, and organ dysfunction can shift over hours, and this preprint argues that sphingosine-1-phosphate may move in step with that biological drift. In a prospective emergency department cohort, declining plasma S1P over time was associated with higher 60-day mortality in patients with sepsis, while a single baseline measurement carried little prognostic weight on its own.
The signal is biologically plausible. S1P is a bioactive lipid tied to endothelial barrier integrity and immune regulation, two processes that unravel early in sepsis. When the vascular lining becomes leaky and leukocyte trafficking becomes dysregulated, circulating S1P may fall as the illness intensifies, making serial measurement more informative than a one-time sample taken at presentation.
The study enrolled adults from the emergency department of Wan Fang Hospital between April 2022 and October 2024. Plasma S1P was measured by ELISA on day 1, day 3, and again before discharge or death. Among 278 participants, 156 had sepsis, with the remainder divided between non-septic infection and non-infected controls. Baseline S1P was lower in sepsis, at 82.2 ng/mL with an interquartile range of 47.8 to 141.1, compared with 129.2 ng/mL in non-septic infection and 132.8 ng/mL in non-infected controls.
Serial measurements separated risk better than baseline values
The sharpest finding came from the trajectory analysis. In the sepsis cohort, 101 patients fell into the descending S1P trajectory group and 55 into the ascending group. The descending group included low-decreasing, low-stable, and high-decreasing patterns, while the ascending group captured the remaining profiles. Patients in the descending category had a markedly higher hazard of 60-day death, with an adjusted hazard ratio of 3.43 and a 95% confidence interval from 1.11 to 10.58.
One blood draw was not enough.
Baseline S1P, despite being lower in sepsis than in controls, did not independently predict 60-day mortality. The adjusted hazard ratio was 1.004 per 10 ng/mL decrease, with a 95% confidence interval of 0.977 to 1.032 and a p value of 0.803. In practical terms, the first measurement captured case severity at a single point, but not the direction of the illness. The biology of sepsis is dynamic, and the marker behaved like a moving target rather than a fixed threshold.
Time-varying analysis strengthened that interpretation. Each 10 ng/mL decrease in S1P over time was associated with a 3.5% higher hazard of death, with an adjusted hazard ratio of 1.035, a 95% confidence interval of 1.002 to 1.076, and a p value of 0.041. The effect size is modest per increment, but in a syndrome where multiple organ systems can deteriorate in parallel, a persistent downward trend may mark patients whose endothelial and immune dysfunction is not recovering.
Why a declining lipid marker may matter at the bedside
S1P has attracted attention because it sits at the interface of vascular permeability and leukocyte behavior. In sepsis, capillary leak, microcirculatory failure, and inflammatory amplification can combine to worsen perfusion and organ injury. A falling S1P concentration may therefore reflect more than epiphenomenon; it may represent a circulating footprint of a failing vascular barrier and a worsening host response.
That does not turn S1P into a ready-to-use bedside test. The preprint does not provide a clinical cutoff for decision-making, and the confidence interval around the trajectory hazard ratio is wide, which is a reminder that the cohort was not large enough to pin down a precise predictive threshold. Still, the contrast between baseline and longitudinal findings is hard to ignore. Prognosis in sepsis may depend less on where a patient starts and more on whether the biology begins to recover.
The emergency department setting also matters. Sepsis is often first recognized when clinicians are trying to decide who needs escalation, close monitoring, or rapid transfer to higher-acuity care. A biomarker that changes in parallel with survival could become useful if future studies show that serial decline identifies patients who need more aggressive surveillance or earlier support. For now, this remains a prognostic observation rather than an intervention guide.
The cohort design adds real-world credibility, but it also leaves important questions unanswered. A prospective observational study can link S1P trajectories to mortality, yet it cannot prove that the biomarker drives outcomes or that changing S1P would change the course of sepsis. The data also do not establish whether S1P is superior to existing clinical scores, whether it adds value alongside lactate or other inflammatory markers, or whether the pattern holds across different infection sources and levels of organ failure.
Even so, the biological message is consistent. Sepsis is not a static condition, and neither is the circulation of S1P. A downward trajectory appears to mark a subgroup with substantially higher short-term mortality, while a single early value does not carry the same prognostic power. If future validation studies confirm this pattern, serial S1P measurement could become part of the broader effort to track endothelial injury and immune collapse before the bedside picture becomes irreversible.